2007 phamracy newsletter april 2007

Antibiotic Subcommittee Report Infectious Diseases Society of America (IDSA) & the Society for Health-care Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship – Antibiotic Subcommit- tee members and P&T Members strongly recommend having an ID Clini- cal Pharmacist in the University Hospital. Human Papillomavirus (Type 6,11,16,18) Recombinant Vaccine Auto-Sub All Quinine Sulfate All Strengths to 325mg. Keep 325mg, Delete 324mg, 200mg, 300mg, 260mg - Approved All UMDNJ-University Hospital Pre-printed Standing Orders Sets which contain Medication orders must be reviewed and approved by Pharmacy and Therapeutics Committee (P&T) prior to submission to MEC. Approved Hemodialysis Physician Standing Orders – Approved Ventilated Associated Pneumonia (VAP) Treatment Order Set – Approved Medication Order Sets for Ophthalmic Surgical Patients – Approved Sepsis Order Sets P&P and Xigris® Drotrecogin alpha activated as-sessment and dosing protocol – Approved Administration of Intravenous Medications Updated Policy – Approved Floor Stock Sheet for Clinics Policy and Procedure – Approved In order to meet the UMDNJ-UH Standing Or- ders Sets policy and procedure (policy # 717- 100-401), the JCAHO Medication Management Standard MM.3.20 (Non-approved Dangerous Abbreviations) and MM.2.10 (Pharmacy and Therapeutics Committee Function), all UMDNJ- a. The patients limit has increased to 100 University Hospital Pre-printed Standing Orders Sets which contain medication orders must be first notification of intent more than one reviewed and approved by Pharmacy and Thera- peutics Committee (P&T) prior to submission to b.The patients limit is still 30 for physi- cians who submitted their first notifica- It is the policy of UMDNJ-University Hospital to use Standing Order Sets to promote the highest quality of care for patients by reducing unin- tended and unwarranted variation in care and by Gardisil is used for girls and women 9-26 providing a useful, efficient management tool for years old to prevent diseases associated clinicians who have order-writing privileges. with infection with human papillomavirus (HPV) types 6,11, 16, and 18, including genital warts, precancerous cervical, vagi-nal or vulvar lesions, and cervical cancer. Gardisil® is administered in 3 separate 0.5 mL intramuscular injection at 0, 2 and 6 months. Each dose costs about $120; the cost of a full course will be about $360.00. Auto-Sub All Quinine Sulfate All Strength to 325mg Pharmacy dept. is going to keep 325 mg Quinine Sulfate only. All other strengths 324mg, 200mg, 300mg and 260 mg will be deleted from formulary. ($0.14 vs. $3,40). Automatic therapeutic exchange from 324mg, 200mg, 300mg and 260 mg to 325mg except for malaria treatment 650mg will be dispensed as 2 tablets of 325mg. Administration of Intravenous Medications –Updated Policy Main Key Points from the policy: All health care professionals shall follow the IV push guidelines “UMDNJ- University Hospital Intrave-nous Drug Administration Guideline for Adults” approved by Pharmacy and Therapeutics Committee (P&T) and Medical Executive Committee (MEC) If MD writes an IV drug order for IV Push medication, this will automatically be dispensed and ad- ministered as an IV Push, unless otherwise stated by MD through spcific directions “Do Not Ex-change” or “DAW” or “Dispense As Written” (UH Automatic Therapeutic Exchange policy - Issue No. 707-500-122: approved by MEC) (a) Pepcid 20 mg IVPB daily will be dispensed and administered as Pepcid 20 mg IVP daily (b) Pedcid 20mg IVPB daily (DAW) will be dispensed and administered as Pepcid 20 mg IVPB daily All IV push medications will be documented on the MAR. New Procedure for Dispensing of Levaquin 500 mg IVPB • Pharmacy Department will dispense all Levaquin® IVPB with the foil wrap on. • The patient label will be attached on one corner to allow the RN to pull the label off the foil pack and place the label directly on the IV bag. • Once removed from the outer foil, the Levaquin IV bag has a 24 hour expiration. This new proc- ess will help minimize product loss due to short dating and compromised sterility.

Source: http://www.umdnj.edu/uhnetweb/pharmacy/PharmNewsletter_April_2007.pdf


1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND COMPANY/UNDERTAKING 'XYLOCAINE' INJECTIONS WITH ADRENALINE Address/Phone No. : DENTSPLY Ltd 2. COMPOSITION/INFORMATION ON INGREDIENTS Chemical Composition Contains: adrenaline/epinephrine (0.0005-0.001%) : Local anaesthetic solution for use in infiltration anaesthesia, peripheral and central nerve blocks. HAZARDOUS INGR

Microsoft word - august 2008 newsletter.doc

DONCASTER PCT PRESCRIBING NEWSLETTER AUGUST 2008 Stronger warnings recommended for etoricoxib Following a review conducted as part of a licence ƒ Etoricoxib must not be used in patients extension application, the European Medicines whose blood pressure is persistently above Agency has recommended that the warnings and 140/90 mmHg contraindications for etoricoxib are strength

Copyright © 2010 Health Drug Pdf